Home » Stocks » EVLO

Evelo Biosciences, Inc. (EVLO)

Stock Price: $15.71 USD 1.69 (12.05%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 725.63M
Revenue (ttm) n/a
Net Income (ttm) -87.22M
Shares Out 46.17M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $15.71
Previous Close $14.02
Change ($) 1.69
Change (%) 12.05%
Day's Open 13.75
Day's Range 13.75 - 15.77
Day's Volume 173,743
52-Week Range 3.21 - 15.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

–EDP1815 was well tolerated, and showed clinically meaningful and consistent changes in all measured  physician-reported outcomes –

GlobeNewsWire - 2 weeks ago

-- Expand EDP1815 Phase 2 program to include atopic dermatitis; interim clinical results expected in 1Q 2022 -- -- Accelerate delivery of interim clinical data from EDP1815 Phase 2 psoriasis t...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidat...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which...

Seeking Alpha - 2 months ago

Evelo Biosciences seeks to harass the ability of microbes in the gut to direct the immune system. The approach is novel and unproven and thus investing is a very high risk proposition.

Seeking Alpha - 2 months ago

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

-- Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis ---- Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 ...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting b...

GlobeNewsWire - 3 months ago

–Data expected in 1Q 2021– –Data expected in 1Q 2021–

GlobeNewsWire - 3 months ago

– Interim data expected by mid-2021 –

Zacks Investment Research - 3 months ago

Evelo Biosciences (EVLO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically...

Seeking Alpha - 5 months ago

Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

– FDA authorization of IND for Phase 2 trial of EDP1815 in COVID-19 in the U.S.; data expected in 4Q 2020 ––Achieved regulatory and ethics authorization for Phase 2 dose ranging trial for EDP1...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically ...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered, sy...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered, sy...

GlobeNewsWire - 7 months ago

—Phase 2/3 platform trial sponsored by Cambridge University Hospitals NHS Foundation Trust— —Experimental therapies with potential to prevent and treat complications of COVID-19— —EDP1815 se...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically ...

Zacks Investment Research - 7 months ago

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 7 months ago

Evelo Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 8 months ago

Evelo Biosciences Inc (EVLO) CEO Simba Gill on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

–Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during 2H 2020––Selected enteric capsule formulation of EDP1815 for Pha...

GlobeNewsWire - 8 months ago

—Early intervention in hospitalized patients could help prevent progression of disease— —EDP1815 has demonstrated favorable tolerability and anti-inflammatory activity in a prior clinical tr...

GlobeNewsWire - 9 months ago

Industry veteran brings deep experience in drug development from leadership roles at Regeneron and Vertex Industry veteran brings deep experience in drug development from leadership roles at R...

GlobeNewsWire - 10 months ago

CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically...

Seeking Alpha - 11 months ago

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

-- EDP1815 Phase 2 Interim Data in Psoriasis Expected by Year-End 2020 -- CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotec...

GlobeNewsWire - 1 year ago

Industry veteran brings expertise in manufacturing, R&D, and operations from leadership roles at Novartis, Eli Lilly, and Moderna Industry veteran brings expertise in manufacturing, R&D, and o...

Seeking Alpha - 1 year ago

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Evelo Biosciences (EVLO) CEO Simba Gill on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q1 2019 Results - Earnings Call Transcript

About EVLO

Evelo Biosciences, a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthrit... [Read more...]

Industry
Biotechnology
IPO Date
May 9, 2018
CEO
Dr. Balkrishan Gill
Employees
98
Stock Exchange
NASDAQ
Ticker Symbol
EVLO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for EVLO stock is "Buy." The 12-month stock price forecast is 17.50, which is an increase of 11.39% from the latest price.

Price Target
$17.50
(11.39% upside)
Analyst Consensus: Buy